ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

Journal and News Scan

Source: Journal of Thoracic Oncology
Author(s): Adam J. Friedant, Elizabeth A. Handorf, Stacey Su, Walter J. Scott

This systematic review assessed outcomes of surgery for thymomas treated with open vs minimally invasive approaches.  The vast majority of tumors were Masaoka I and II.  Minimally invasive approaches were associated with shorter LOS and less blood loss.  Complication rates were similar between  the groups, as were rates of R0 resection and recurrence. 

Source: Annals of Thoracic Surgery
Author(s): Amr F. Barakat, Marwan Saad, Ahmed Abuzaid, Amgad Mentias, Ahmed Mahmoud, Islam Y. Elgendy

Comprehensive review article on the role of periperative statin therapy in patients undergoing coronary revascularization.  

Source: Circulation
Author(s): Harskamp RE, Alexander JH, Ferguson TB Jr, Hager R, Mack MJ, Englum B, Wojdyla D, Schulte PJ, Kouchoukos NT, de Winter RJ, Gibson CM, Peterson ED, Harrington RA, Smith PK, Lopes RD.

The authors of this paper aimed to study the frequency and predictors of internal mammary artery (IMA) failure in 1539 patients who underwent IMA revascularization of the left anterior descending (LAD) artery. IMA failure was defined as >75% stenosis at a follow-up of 12-18 months.  They found that IMA failure occured in 8.6%. IMA failure was associated with LAD stenosis <75% (odds ratio 1.76), not having diabetes mellitus (OR 1.82) and an additional bypass graft to the diagonal branch (OR 1.92). IMA failure was associated with higher rates of acute clinical events after follow-up angiography.   The investigators conclude that these findings suggest that the benefit of CABG in moderate LAD stenosis without functional ischemia could be matter of debate. 

Source: Annals of Surgery
Author(s): In, Haejin; Palis, Bryan E.; Merkow, Ryan P.; Posner, Mitchell C.; Ferguson, Mark K.; Winchester, David P.; Pezzi, Christopher M.

30-day and 90-day mortality rates were compared using information from the National Cancer Data Base 2007-2011.  Among nearly 16,000 esophagectomies, the 30-day mortality rate was 4.2% and the 90-day rate was 8.9%.  90-day mortality was uniquely associated with tumor location, tumor stage, and receipt of neoadjuvant therapy.

Source: European Journal of Cardio-Thoracic Surgery
Author(s): Alexander Romanova,*, Kinga Goscinska-Bisb, Jaroslaw Bisb, Alexander Chernyavskiya, Darya Prokhorovaa, Yana Syrtsevaa, Vitaliy Shabanova, Sergey Alsova, Alexander Karaskova, Marek Dejab, Michal Krejcab and Evgeny Pokushalova

The authors performed a randomized control study of 178 patients with heart failure and systolic dyssynchrony who were accepted for CABG, randomizing the participants into two groups:  CABG alone (n=87) and CABG + concomitant epicardial CRT (n=91).  CRT was activated postoperatively.  At a mean follow-up period of 55 months, the mortality rate of the CABG group was 36% and that of the CABG + CRT group was 15%.  Moreover, all-cause mortality, cardiac death, and hospital readmissions were significantly lower for the CABG + CRT group.

It is known that not all patients with potential indications for CRT undergoing CABG will meet the criteria for CRT postoperatively.  The question is whether performing CRT at the time of CABG in all such patients is a cost-effective strategy.

 

Source: Journal of Thoracic Oncology
Author(s): Peter Goldstraw, Kari Chansky, John Crowley, Ramon Rami-Porta, Hisao Asamura, Wilfried E.E. Eberhardt, Andrew G. Nicholson, Patti Groome, Alan Mitchell, Vanessa Bolejack, on behalf of the International Association for the Study of Lung Cancer Staging and Prognostic Factors Committee, Advisory Boards, and Participating Institutions

This long-awaited lung cancer staging update serves as the model for the AJCC 8 update that will be published in the near future.  The primary changes involve T status and an expansion of M status to include a single distant metastasis as T4c.  Stage IA is now subdivided into 3 stages, IIIC has been added, and stage IV has been expanded into IVA and IVB.  Overall, the previous 7 TNM stages have been expanded to 11. 

Source: American Journal of Clinical Pathology
Author(s): Lisa M. Rooper, Syed Z. Ali, Matthew T. Olson

Are we removing enough pericardial fluid to allow a diagnosis of malignant effusion?  The authors reviewed  480 pericardiocentesis specimens by comparing the percentage of malignant diagnoses ("malignancy fraction") by the volume submitted for analysis.  Using pericardial biopsy as the standard,  the sensitivity for the diagnosis of malignancy was 18.1% vs. 10.6% if more or less than 60 mL was submitted, respectively.  These results beg the following questions:  1.  Did patients with pericardial malignancies tend to have larger effusions and therefore larger aspirations?  2.  Was more fluid aspirated or submitted in patients with a higher index of suspicion for malignancy?

Source: American Journal of Surgery
Author(s): Lori DeFreest, Marcel Tafen, Avinash Bhakta, Ashar Ata, Stephen Martone, Owen Glotzer, Kevin Krautsak, Carl Rosati, Steven C. Stain, Daniel Bonville

This retrospective single-center study evaluated outcomes of patients treated for flail chest using open reduction and fixation (ORIF) or non-operative management (NOM).  The 41 ORIF and 45 NOM patients were similar in demographics and injury severity.  Hospital and ICU LOS were longer in the ORIF group.  The ORIF group also trended towards longer time on the ventilator.  Further knowledge regarding appropriate patient selection criteria for ORIF in the management of flail chest is needed.

Source: Journal of Thoracic Oncology
Author(s): Brandon Stone, Victor S. Mangona, Matthew D. Johnson, Hong Ye, and Inga S. Grills

The goal of this study was to present the changes in pulmonary function after SBRT in 127 patients with clinical stage I NSCLC or a single lung metastasis. These patients were either too high risk for an operation or preferred a non-operative treatment approach. PFTs were measured at several time points including within 10 weeks of starting SBRT and then 6 weeks, 3 months, 6 months, 9 months, 1 year and 2 years after treatment (median follow-up was 25 months). At 12 months, there were significant decreases in TLC (-3.6%), FVC (-5.7%), FVC % predicted (-4.6%), FEV1 (-4.1%), and corrected DLCO (-5.2%) compared to baseline. At 24 months, there were significant decreases in FVC (-8.9%), and FEV1 (-7.6%) compared to baseline. When compared to surgical series, the reductions in lung function appear later and are smaller.  

Source: Annals of Thoracic Surgery
Author(s): B. Jason Bowles, MDcorrespondenceemail, Jo Puntil-Sheltman, MS, CCC BCS-S

The authors tested a group of 176 patients undergoing cardiac surgery for dysphagia both preoperatively and postoperatively.  Preoperatively, 8.5% of patients failed the swallow test.  Postoperatively, 21.6% failed the test.  All patients who failed preoperatively also failed postoperatively.  Thus, approximately 40% fo patients who have postop dysphagia had evidence of dysphagia preoperatively.  

These results beg the question:  Ought we to be screening at-risk patients for dysphagia preoperatively?  If so, how would this change management postop?

Pages